Effective treatment of chronic fatigue syndrome

Integrative Medicine

Volumn 4, Issue 4, 2005, Pages 24-29

  Teitelbaum, Jacob ^a  

^a Annapolis Center for Effective CFS/Fibromyalgia Therapies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASCORBIC ACID; CALCIUM; CARISOPRODOL; CLONAZEPAM; CORTISONE; CYCLOBENZAPRINE; FLUCONAZOLE; GABAPENTIN; GLYCYRRHIZA EXTRACT; HYDROCORTISONE; IBUPROFEN; LEVACECARNINE; LIOTHYRONINE; MAGNESIUM; MELATONIN; PANTOTHENIC ACID; POTASSIUM MAGNESIUM ASPARTATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RIBOSE; ROFECOXIB; SALICIN; THYROXINE; TRAZODONE; UBIDECARENONE; UNINDEXED DRUG; VITAMIN B GROUP; ZOLPIDEM;

ADRENAL INSUFFICIENCY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ESTROGEN DEFICIENCY; HUMAN; HYPOTHALAMUS DISEASE; IMMUNOPATHOLOGY; INFECTION; MYOFASCIAL PAIN; NUTRITIONAL DEFICIENCY; PAIN; PREVALENCE; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; THYROID FUNCTION; TREATMENT OUTCOME;

EID: 33744950311     PISSN: 1546993X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population," Arthritis Rheum. 1995;38(1):19-28.
2. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7:362-368.
3. Teitelbaum JE, Bird B, Greenfield RM, et al. Effective treatment of CFS and FMS: a randomized, double-blind placebo-controlled study. J Chronic Fatigue Syndrome. 2001;8:3-28.
4. Travell JG, Simons DG. The Trigger Point Manual - Volume 1. Baltimore, MD: Williams & Wilkins; 1983.
5. Skootsky SA, Jaeger B, Oye RK. Prevalence of myofascial pain in general internal medicine practice. West J Med. 1989;151:157-160.
6. Teitelbaum J, Bird B. Effective treatment of severe chronic fatigue: a report of a series of 64 patients. J Musculoskel Pain. 1995;3(4):91-110.
7. Blatman H. Effective treatment of fibromyalgia and myofascial pain. J Am Acad Pain Mgmt. 2002;12:67-68.
8. Demitrack MA, Dale K, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metabol. 1991;73(6):1223-1234.
9. Behan PO. Post-Viral Fatigue Syndrome Research. In: The Clinical and Scientific Basis of Myalgic Encephalitis and Chronic Fatigue Syndrome. Hyde B, Goldstein J, Levine P, eds. Ottawa, Ontario, Canada: Nightingale Research Foundation; 1992:238.
10. Plioplys AV, Plioplys S. Amantadine and L-Carnitine treatment of chronic fatigue syndrome. Neuropsychobiol. 1997;35(1):16-23.
11. Kuratsune H, Yamaguti K, Takahashi M, et al. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis. 1994;18(3, Suppl 1): S62-S67.
12. Fleming T, ed. Jamaica Dogwood: PDR for Herbal Medicines. Montvale, NJ: Medical Economics Company; 1998:428-429.
13. Humulus Lupus, monograph. Altern Med Rev. 2003;8(2):190-192.
14. Cronin JR. Passionflower - reigniting male libido and other potential uses. Altern Complem Ther. April 2003;89-92.
15. Dhawan K, Kumar S, Sharma A, et al. Reversal of morphine tolerance and dependence by Passiflora Incarnata. Pharm Biol. 2002;40(8):576-580.
16. Hadley S, Petry, JJ. Valerian. Am Family Phys. 2003;67(8):1755-1758.
17. Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ. 1996;312(7042):1339.
18. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Internal Med. 2000;160:526-534.
19. Available at: http://www.aace.com/pub/tam2003/press.php.
20. Lowe JC, Garrison RL, Reichman AJ, Yellin J, Thompson M, Kaufman D. Effectiveness and safety of T3 therapy for euthyroid fibromyalgia: a double-blind, placebo-controlled response driven crossover study. Clin Bull Myofascial Ther. 1997:2 (2/3):31-58.
21. Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind, placebo-controlled, crossover study. Clin Bull Myofascial Ther. 1997;2(2/ 3):91-124.
22. Neeck G, Riedel W. Thyroid function in patients with fibromyalgia syndrome. J Rheumatol. 1992;19(2,3):1120-1122.
23. Faglia G, Bitensky L, Pinchera A, et al. Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin. J Clin Endocrinol Metabol. 1979;48(6):989-998.
24. Skinner GRB, Holmes D, Ahmad A, et al. Clinical response to thyroxine sodium in clinically hypothyroid but biochemically euthyroid patients. J Nutr Environ Med. 2000;10(2):115-125.
25. Nordyke RA, Reppun TS, Madanay LD, et al. Alternative sequences of thyrotropin and free thyroxine assays for routine thyroid function testing: quality and cost. Arch Internal Med. 1998;158(3):266-272.
26. Griep EN, Boersma JN, de Kloet ER. Altered reactivity of the hypothalamic-pituitary axis in the primary fibromyalgia syndrome. J Rheumatol. 1993;20(3):469-474.
27. McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome and a comparison with rheumatoid arthritis. J Rheumatol. 1993;25:469-474.
28. Jefferies WM. Safe Uses of Cortisol. 2nd edition, monograph. Springfield, IL: Charles C. Thomas; 1996.
29. Jefferies WM. Low-dosage glucocorticoid therapy: an appraisal of its safety and mode of action in clinical disorders, including rheumatoid arthritis. Arch Internal Med. 1967;119(3):265-278.
30. McKenzie R, O'Fallon A, Dale J, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA. 1998;280(12):1061-1066.
31. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metabol. 1994;78(6):1360-1367.
32. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005;54:765-769.
33. Fukui M, Kitagawa Y, Nakamura N, et al. Association between urinary albumin excretion and serum dehydroepiandrosterone sulfate concentration in male patients with type 2 diabetes: a possible link between urinary albumin excretion and cardiovascular disease. Diabetes Care. 2004;27(12):2893-2897.
34. Wright JV, Lenard L. Maximize Your Vitality and Potency, for Men over 40. Petaluma, California: Smart Publications; 1999
35. Vliet EL. Screaming To Be Heard: Hormone Connections Women Suspect...and Doctors Ignore. New York, NY: M. Evans and Company; 1995.
36. Ivker RS. Sinus Survival. New York, NY: Tarcher/Putnam; 2000.
37. Becker WM, Reece JB, Poenie MF, et al. The World of The Cell. 3rd edition. San Francisco, CA: Benjamin Cummings; 1996.
38. Regland B, Andersson M, Abrahamsson L, et al. Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. Scandinavian J Rheumatol. 1997;26(4):301-307.
39. Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin deficiency in the framingham elderly population. Am J Clin Nutr. 1994;60(1):2-11.
40. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytoses. New Engl J Med. 1988;318(26):1720-1728.
41. Beck WS. Cobalmin and the nervous system. New Engl J Med. 1988;318(26):1752-1754.
42. Marz RW, Kemper F. Willow bark extract - effects and effectiveness. Status of current knowledge regarding pharmacology, toxicology and clinical aspects (article in German). Wien Med Wochenschr. 2002;152(15-16):354-359.
43. Chrubasik S, Kunzel O, Black A, et al. Potential economic impact of using a proprietary willow bark extract in outpatient treatment of low back pain: an open non-randomized study. Phytomed. 2001;8(4):241-251.
44. Campbell J. "The Power of Myth" (interview by Bill Moyers, 1987 original broadcast, National Public Radio).